BioCentury
ARTICLE | Clinical News

Multaq dronedarone regulatory update

February 28, 2011 8:00 AM UTC

sanofi-aventis received 2 warning letters from FDA regarding the company's failure to adequately address cGMP deficiencies and postmarketing reporting violations identified during FDA inspections last...